Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).

Sant P. Chawla,Gerald Steven Falchook,Melissa Amber Burgess,James L. Chen,Robin L. Jones,Victoria S Chua,Coya Tapia,Jessica Ainscough,Anthony Hamlett,Melinda S. Merchant,Rashmi Chugh

Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).

2021

Sant P. Chawla
Gerald Steven Falchook
Melissa Amber Burgess
James L. Chen
Robin L. Jones
Victoria S Chua
Coya Tapia
Jessica Ainscough
Anthony Hamlett
Melinda S. Merchant
Rashmi Chugh

11563Background: ES is a rare, aggressive subtype of STS for which cytotoxic chemotherapy has limited effectiveness. TAZ, an FDA-approved EZH2 inhibitor, has shown single-agent clinical activity an...

Keywords:

Placebo-controlled study
cytotoxic chemotherapy
Tazemetostat
Cancer research
Medicine
double blind
Soft tissue sarcoma
Epithelioid sarcoma
Doxorubicin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations